Thank you for your interest. The I-MOVE+ project (2015-2018) is over, and this website will no longer be updated. However, activities to monitor vaccine effectiveness in Europe are ongoing and can be found on the I-MOVE and SpiDnet websites for influenza (coming soon) and pneumococcal vaccines (https://sites.google.com/a/epiconcept.fr/ipd-surveillance/) The primary objective of work package 3 (WP3) is to estimate the effectiveness (direct effect) and impact (overall and indirect effect) of available pneumococcal vaccines against invasive pneumococcal disease (IPD), community-acquired pneumonia (CAP) and potentially against other respiratory diseases in adults 65 years and older. This will be accomplished by using and enhancing the available surveillance systems and existing data sources in the participating countries to: 1. estimate the level of individual protection and its duration from available pneumococcal vaccines against specific and non-specific pneumococcal disease outcomes; 2. estimate the reduction in pneumococcal disease burden in the elderly which is due to reduced transmission resulting from routine childhood PCV programmes (herd protection, i.e. indirect effect); 3. understand the timing and magnitude of potential increase in disease from serotypes not included in the infant PCVs (replacement disease); 4. determine the best study designs and data sources to provide evidence on effectiveness and impact for informing public health actions at regional, national and supranational levels. Leaders: National Institute for Health and Welfare (THL) & EpiConcept Participants:
Generic protocols:
|
WP3: Pneumococcal vaccines
Subpages (1):
Resources PCV vaccines